With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...
Ollie's Bargain Outlet and United Natural Foods both topped earnings estimates, lifting the retail stocks early Tuesday.
The sales surge signals the chip maker’s continued momentum amid the artificial-intelligence boom, though investors weren't ...
Morgan Stanley Smith Barney will pay a $15 million penalty as part of a settlement with the Securities and Exchange ...
Stocks, bonds and the dollar saw small moves, with traders unwilling to make any significant bets as they await key inflation data for clues on whether the Federal Reserve will cut or hold rates next ...